Reflecting on 2024: a category sweep of the Nobels, AI enabled clinical readouts, and the first trillion dollar pharma in sight.
We stand on the shoulders of giants. Looking to 2025: This is just the beginning. Make no small plans.
For large pharma companies serious about integrating ML throughout their organizations, I believe they'll need infrastructure like what @tamarindbio has created.
With so many open and closed source solutions, a constantly changing model backdrop, pipelines that need
We’re proud to share that @tamarindbio has been selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. @EliLillyandCo TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models
every year @newlimit, we host friends at the lab & share our progress
for 2026, we announced:
- 2X increase in discovery rates with AI systems
- new program for endothelial cells
- 0 -> 1 medicines headed to the clinic
- accelerating recovery from alcohol
some highlights --
Congrats to Deniz, Sherry and @tamarindbio team on the partnership with Lilly! Excited to announce that Lilly's TuneLab model initiative will be solely powered by Tamarind's platform.
There are more high performance open and closed-source bio ML models now than ever. Tamarind
We’re proud to share that @tamarindbio has been selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. @EliLillyandCo TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models
2 years ago Chai was a small team led by @joshim5 & @jackdent working out of the Dimension offices
today they are leading the charge to reinvigorate western pharma and biotech. Lilly and Pfizer are partners. the majority of pharma queuing up..
the rate of progress: staggering
Today we’re launching @chaidiscovery, led by @joshim5 & his polymathic world class cofounders. We’re also open sourcing Chai-1: a state of the art frontier model for biomolecular interactions. @_DimensionCap has co-led the founding round alongside Thrive & OpenAI
Today we are announcing our collaboration with Pfizer to put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.
It's been amazing to watch @joshim5, @jackdent, and team work at speed.
This is the wrong time to be a goalpost mover or a chronic under-estimator of ML velocity, and my team at @_DimensionCap would agree.
Chai is speed-running what I thought would take years and years. I'm
Today we are announcing our collaboration with Pfizer to put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.
Today we are announcing our collaboration with Pfizer to put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.
New Limit just raised $435 million. This is, in part, because they've had a massive breakthrough on reversing the age of the liver with their new brand of genetic reprogramming drugs.
For the first time, NewLimit's co-founder and president Jacob Kimmel details the company's
📣 New @_DimensionCap essay on training data recipes for bio-focused ML models, by @bauer_lesavage
The data market is pretty vibrant right now. Frontier labs are buying big chunks of targeted data, multi-modal data, even bio-data.
Bio platform companies are benefitting from
great to see GLUE (@MonteRosaTx) get a very well deserved call out today as they pioneer in designing drugs that have potential to help millions of lives across onc and i&i whilst unlocking new classes of mechanisms and modalities
Dimension has co-led a $100M financing into @MonteRosaTx. Thrilled to support @markus_warmuth and the entire team at the cutting edges of geometric deep learning, next gen proteomics, and molecular glue degraders.
almost exactly 3 years ago Dimension led a $40M Series A in @newlimit, inspired by the pioneering vision of @jacobkimmel@byersblake and @brian_armstrong.
today, we announce a $435M Series C led by Founders Fund w Thrive and Greenoaks as new partners.
lets go chart the future.
Following breakthrough results, we’re bringing longevity medicine to human trials.
We’ve raised a $435M Series C led by @foundersfund to make it happen.
Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.